10:56 AM EST - Oncolytics Biotech® Inc. : Announced positive clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer. Patients receiving treatment with the recommended phase 2 dose of pelareorep in combination with FOLFIRI/B (irinotecan, fluorouracil, leucovorin, plus bevacizumab) had progression free survival of 65.6 weeks and an overall survival of 107.5 weeks, which exceeded expectations when compared to historical data. Oncolytics Biotech® Inc.
shares T.ONC are trading down $0.07 at $4.07.
